Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma - PubMed (original) (raw)
doi: 10.1038/leu.2010.108. Epub 2010 May 20.
K Rsitow, D J Inwards, S M Ansell, I N Micallef, P B Johnston, T M Habermann, T E Witzig, J P Colgan, G S Nowakowski, C A Thompson, S N Markovic
Affiliations
- PMID: 20485372
- DOI: 10.1038/leu.2010.108
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
L F Porrata et al. Leukemia. 2010 Jul.
Abstract
A specific predictor during routine follow-up to ascertain risk for relapse after standard chemotherapy in non-Hodgkin's lymphoma (NHL) has not been identified. Thus, we studied absolute lymphocyte count (ALC) as a marker of poststandard chemotherapy (rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP)) NHL relapse in patients with diffuse large B-cell lymphoma (DLBCL). ALC was obtained at the time of confirmed relapse and at last follow-up. From 2000 until 2006, 149 consecutive DLBCL patients, originally diagnosed, treated with R-CHOP and followed up at Mayo Clinic, Rochester, were included in this study. Patients at last follow-up without relapse (N=112) had a higher ALC compared with those with relapsed lymphoma ((N=37) median ALC x 10(9)/l of 1.43 (range: 0.33-4.0) versus 0.67 (range: 0.18-1.98), P<0.0001, respectively). ALC at the time of confirmed relapse was a strong predictor for relapse with an area under the curve =0.91 (P<0.0001). An ALC <0.96 x 10(9)/l at the time of confirmed relapse had a positive predictive value of 72% and a positive likelihood ratio of 7.4 to predict relapse after R-CHOP in DLBCL. Patients with an ALC>or=0.96 x 10(9)/l (N=103) had a cumulative incidence of relapse of 6 versus 79% with an ALC <0.96 x 10(9)/l (N=46) (P<0.0001). This study suggests that lymphopenia measured by ALC can be used as a marker to assess risk of DLBCL relapse during routine follow-up after standard chemotherapy.
Similar articles
- New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Porrata LF, et al. Biol Blood Marrow Transplant. 2010 Mar;16(3):376-83. doi: 10.1016/j.bbmt.2009.10.029. Epub 2009 Oct 31. Biol Blood Marrow Transplant. 2010. PMID: 19883776 - Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Porrata LF, et al. Am J Hematol. 2009 Feb;84(2):93-7. doi: 10.1002/ajh.21337. Am J Hematol. 2009. PMID: 19123458 - Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R. Guirguis HR, et al. Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review. - Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH, Connors JM. Sehn LH, et al. Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34. Oncology (Williston Park). 2005. PMID: 15934515 Review.
Cited by
- Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma.
Huo Z, Chen F, Zhao J, Liu P, Chao Z, Liu K, Zhou J, Zhou D, Zhang L, Zhen H, Yang W, Tan Z, Zhu K, Luo Z. Huo Z, et al. Clin Exp Med. 2023 Dec;23(8):4665-4672. doi: 10.1007/s10238-023-01249-0. Epub 2023 Nov 8. Clin Exp Med. 2023. PMID: 37938466 Free PMC article. - Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.
Battella S, Cox MC, La Scaleia R, Di Napoli A, Di Landro F, Porzia A, Franchitti L, Mainiero F, Ruco L, Monarca B, Santoni A, Palmieri G. Battella S, et al. Cancer Immunol Immunother. 2017 Oct;66(10):1295-1306. doi: 10.1007/s00262-017-2026-7. Epub 2017 May 29. Cancer Immunol Immunother. 2017. PMID: 28555258 Free PMC article. - Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.
Aktipis CA, Kwan VS, Johnson KA, Neuberg SL, Maley CC. Aktipis CA, et al. PLoS One. 2011;6(11):e26100. doi: 10.1371/journal.pone.0026100. Epub 2011 Nov 17. PLoS One. 2011. PMID: 22125594 Free PMC article. - Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.
Zhou S, Xu L, Ma Y, Tang L, Zhang Y, Shi Y, Sun L, Chen Y, Liang B, Zhou Y, Yu K, Shen J. Zhou S, et al. Oncotarget. 2017 Mar 21;8(12):19556-19565. doi: 10.18632/oncotarget.14700. Oncotarget. 2017. PMID: 28107187 Free PMC article. - Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission.
Hawkes EA, Loh Z, Estacio O, Chong G, Ha FJ, Gilbertson M, Grigg A. Hawkes EA, et al. Br J Cancer. 2018 Aug;119(5):546-550. doi: 10.1038/s41416-018-0183-x. Epub 2018 Jul 23. Br J Cancer. 2018. PMID: 30033446 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials